Physician profile
Adrian Ortega
NPI 1124774120
$7,514.79
in general payments reported to CMS, 2019-2025
30 companies · $3,475 in 2025
The $3,475 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $271 · 2023: $1,148 · 2024: $2,621 · 2025: $3,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,203 · Education: $41.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,203.15 |
| Education | $41.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,608.54 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $680.82 | 2022-2025 | Trulance, Xifaxan, Relistor |
| Ardelyx, INC. | $611.16 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $569.21 | 2024-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $452.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $412.50 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $366.31 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $350.08 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $315.88 | 2024 | Voquezna |
| Qol Medical, LLC | $265.39 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $260.49 | 2024-2025 | Omvoh, Zepbound |
| Janssen Biotech, INC. | $231.60 | 2024-2025 | Tremfya, Stelara |
| Novo Nordisk INC | $188.84 | 2025 | Wegovy |
| Celgene Corporation | $160.08 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $157.23 | 2023-2025 | Linzess |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $148.54 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $126.16 | 2023-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $125.33 | 2023-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $113.90 | 2023 | |
| Vivus LLC | $69.55 | 2025 | Pancreaze, Qsymia |
| Pfizer INC. | $55.26 | 2022-2025 | |
| Celltrion USA INC. | $41.09 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $38.33 | 2023 | |
| Braintree Laboratories, INC. | $33.61 | 2024-2025 | Suflave, Sutab |
| Exact Sciences Corporation | $30.59 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $25.30 | 2025 | Uplizna |
| Fresenius Kabi USA, LLC | $25.24 | 2023 | |
| Redhill Biopharma INC. | $19.31 | 2022 | |
| Intra-Sana Laboratories | $18.17 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Alexion Pharmaceuticals, INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.